<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01355445</url>
  </required_header>
  <id_info>
    <org_study_id>VIT-0910</org_study_id>
    <secondary_id>2010-023135-42</secondary_id>
    <nct_id>NCT01355445</nct_id>
  </id_info>
  <brief_title>Vincristine and Irinotecan With or Without Temozolomide in Children and Adults With Refractory/Relapsed Rhabdomyosarcoma</brief_title>
  <acronym>VIT-0910</acronym>
  <official_title>International Randomized Phase II Trial of the Combination of Vincristine and Irinotecan With or Without Temozolomide (VI or VIT) in Children and Adults With Refractory or Relapsed Rhabdomyosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SFCE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international open-label, randomized, multicenter phase II study of VIT and VI for
      the treatment of patients with recurrent or refractory rhabdomyosarcoma. The study will
      evaluate the safety and efficacy of these combinations in patients with recurrent or
      refractory rhabdomyosarcoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The dose of vincristine will be 1.5 mg/m² or 0.05 mg/kg for patient ≤ 10 kg (maximum 2 mg)
      and will be administered by direct intravenous infusion on day 1 and 8 of each course, before
      irinotecan.

      The dose of irinotecan will be 50 mg/m²/d. Irinotecan will be given intravenously over 1 hour
      on days 1-5 of each course, one hour following the administration of temozolomide.

      In the absence of any contraindication (ie known allergies), treatment with oral cefixime 8
      mg/kg once daily (maximum daily dose 400 mg) is recommended and will be started 2 days before
      chemotherapy until day 7.

      Temozolomide will be given according to the randomization. The starting dose of temozolomide
      will be 125 mg/m²/d. The dose of temozolomide will be escalated to 150 mg/m²/day at cycle 2
      for patients who do not experience &gt; grade 3 toxicity of any kind. Temozolomide will be given
      orally, on an empty stomach, on days 1 through 5 of each course.

      Dose reductions and/or administration delays will be performed using specific predefined
      rules to accommodate individual patient tolerance of treatment and to maintain optimal dose
      intensity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective tumour response and progression in each treatment arm.</measure>
    <time_frame>at least 6 weeks (two cycles of treatment)</time_frame>
    <description>The primary efficacy endpoint is defined as the proportion of patients who had a documented complete or partial tumour response occurring after the first 2 cycles of treatment which must be confirmed by a follow-up objective tumour assessment obtained within 4-5 weeks after the initial documentation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the duration of tumor response in each treatment arm</measure>
    <time_frame>During all the study</time_frame>
    <description>The duration of tumour response is defined as the time from first documentation of objective tumour response to the first objective or clinical documentation of progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the time to tumor progression in each treatment arm</measure>
    <time_frame>During all the study</time_frame>
    <description>The time to tumor progression: the time from the date of first treatment administration to the date of first objective or clinical documentation of tumour progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the time to treatment failure in each treatment arm</measure>
    <time_frame>Before 1 year</time_frame>
    <description>The time to treatment failure is defined as the time from the date of first treatment administration to the first documentation of tumour progression, discontinuation of study treatment before one year, or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the overall survival in each treament arm</measure>
    <time_frame>During all the study</time_frame>
    <description>The overall survival is defined as the time from the date of first treatment administration to date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety profile and tolerability in each treatment arm</measure>
    <time_frame>During all the study</time_frame>
    <description>Safety parameters include adverse events and haematology and blood chemistry assays.
Safety evaluations will include characterization of the frequency and severity of adverse events, complete blood cell counts with differential, serum chemistries and electrolytes, and change in weight and body surface area (BSA).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>RHABDOMYOSARCOMA</condition>
  <arm_group>
    <arm_group_label>Vincristine / Irinotecan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vincristine, Irinotecan Vincristine :1.5 mg/m² (max 2mg), IV Irinotecan : Irinotecan 50 mg/m²/d, IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vincristine / Irinotecan / Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vincristine, Irinotecan, Temozolomide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine, Irinotecan</intervention_name>
    <description>D1 and D8: Vincristine 1.5 mg/m² (max 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)
D1 to D5: Irinotecan 50 mg/m²/d, IV
cycle / 21 days</description>
    <arm_group_label>Vincristine / Irinotecan</arm_group_label>
    <other_name>Vincristine-Irinotecan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine, Irinotecan, Temozolomide</intervention_name>
    <description>D1 to D5: Temozolomide 125 mg/m²/d, PO (the dose will be escalated to 150 mg/m²/day at cycle 2 for patients who do not experience &gt; grade 3 toxicity of any kind)
D1 and D8: Vincristine 1.5 mg/m² (maximum 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)
D1 to D5: Irinotecan 50 mg/m²/d, IV
cycle / 21 days</description>
    <arm_group_label>Vincristine / Irinotecan / Temozolomide</arm_group_label>
    <other_name>Vincristine-Irinotecan-Temozolomide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  TUMOR CHARACTERISTICS :

               -  Histologically or cytologically confirmed diagnosis of rhabdomyosarcoma (RMS)
                  (new biopsy recommended)

               -  Relapsed or refractory disease which has failed standard treatment approaches

               -  Patients must have measurable disease defined as lesions that can be measured in
                  3 dimensions by medical imaging techniques such as CT or MRI. Ascites, pleural
                  fluid, bone marrow disease and lesions seen on Tc scintigraphy or PET scan only
                  are not considered measurable for these patients

          -  PATIENT CHARACTERISTICS :

               -  Age &gt; 6 months and ≤ 50 years

               -  Karnofsky performance status (PS) 70-100% (for patients &gt; 12 years of age) OR
                  Lansky Play Score 70-100% (for patients ≤ 12 years of age)

               -  Life expectancy ≥ 12 weeks

               -  Adequate bone marrow function :

                    -  Absolute neutrophil count ≥ 1000/mm3; and ≥ 500/mm3 in case of bone marrow
                       disease

                    -  Platelet count ≥ 100000/mm3 ; and ≥ 75000/mm3 in case of bone marrow disease
                       (transfusion independent)

                    -  Hemoglobin ≥ 8.5 g/dl (transfusion allowed)

               -  Adequate renal function

                    -  Serum creatinine ≤ 1.5 X ULN for age

                    -  If serum creatinine &gt; 1.5 ULN, creatinine clearance (or radioisotope GFR)
                       must be &gt;70 ml/min/1.73 m²

               -  Adequate hepatic function :

                    -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age, except if
                       the patient is known to have Gilbert's syndrome

                    -  ALT and AST ≤ 2.5 times ULN for age

               -  Negative pregnancy test in females with childbearing potential

               -  Fertile patients must use effective contraception

               -  No active &gt; grade 2 diarrhea or uncontrolled infection

               -  No other malignancy, including secondary malignancy

               -  Patient affiliated with a health insurance system. Applicable for French patients
                  only Written informed consent of patient and/or parents/guardians

          -  PRIOR or CONCURRENT THERAPY :

               -  More than 3 weeks since prior radiation therapy to the site of any progressive
                  lesion that will be identified as a target lesion to measure tumor response

               -  At least 3 weeks since prior myelosuppressive therapy (6 weeks for nitrosourea. 2
                  weeks for vincristine, vinblastine, vinorelbine or low dose cyclophosphamide)

               -  No concurrent enzyme-inducing anticonvulsants (EIAC), including phenytoin,
                  phenobarbital or carbamazepine

               -  No concurrent administration of any of the following: rifampicin,
                  voriconazole,itraconazole, ketoconazole, aprepitant, St John's Wort

               -  No prior irinotecan or temozolomide administration

               -  Prior vincristine administration allowed

               -  Concurrent palliative radiation therapy to sites allowed other than the main
                  measurable target

               -  Prior allo- or autologous SCT allowed

        Exclusion Criteria:

          -  Inclusion criteria failure

          -  Concomitant anti-cancer treatment

          -  Know hypersensitivity to any component of study drugs or ingredients

          -  Pregnancy or breast feeding

          -  Patients with rare hereditary problems of galactose intolerance, the Lapp lactase
             deficiency or glucose-galactose malabsorption

          -  Neuromuscular disorders (e.g. Charcot-Marie Tooth disease)

          -  Uncontrolled intercurrent illness or active infection

          -  Unavailable for medical follow-up (geographic, social or psychological reasons)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Sophie DEFACHELLES, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Ocsar Lambet, Lille, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julia CHISHOLM, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden NHS Foundation Trust, Surrey, Uinted Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J.H.M. MD MERKS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emma Children's Hospital, Amsterdam, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michela CASANOVA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Soledad GALLEGO, MDn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Materno - Infantil Vall D' Hebron, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alicia PROBST, PhD</last_name>
    <email>a-probst@o-lambret.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne-Sophie DEFACHELLES, MD</last_name>
    <email>as-defachelles@o-lambret.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Nord</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia PLAYE</last_name>
    </contact>
    <investigator>
      <last_name>Catherine DEVOLDERE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital des Enfants, Groupe Hospitalier Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria MERCHED</last_name>
    </contact>
    <investigator>
      <last_name>Cécile VERITE-GOULARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Morvan</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Typhaine THOMAS</last_name>
    </contact>
    <investigator>
      <last_name>Philippe LE MOINE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille cedex</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline SMIS</last_name>
    </contact>
    <contact_backup>
      <last_name>Maddalena CHEVALIER</last_name>
    </contact_backup>
    <investigator>
      <last_name>Anne-Sophie DEFACHELLES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre LEBLOND, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cyril LERVAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène SUDOUR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas PENEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile GIRAUD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe BERGERON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU, Hôpital d'Enfants de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie ABED</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Claude GENTET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Arnaud de Villeneuve - CHU</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>CHU, Hôpital Mère enfants</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estelle THEBAUD</last_name>
    </contact>
    <investigator>
      <last_name>Sophie DUMOUCEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey GUILMATRE</last_name>
    </contact>
    <investigator>
      <last_name>Guy LEVERGER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soraya DIB</last_name>
    </contact>
    <investigator>
      <last_name>Daniel ORBACH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Bernard</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Violaine GOYEAU</last_name>
    </contact>
    <investigator>
      <last_name>Frédéric MILLOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU - Hôpital Américain</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>CHU Rennes - Hôpital Sud</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle DEBROISE</last_name>
    </contact>
    <investigator>
      <last_name>Sophie TAQUE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU St Etienne - Hôpital Nord</name>
      <address>
        <city>Saint-Etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine SOLER</last_name>
    </contact>
    <investigator>
      <last_name>Claire BERGER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Hôpital des enfants</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwennaëlle ALPHONSA</last_name>
    </contact>
    <investigator>
      <last_name>Marie-Pierre CASTEX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>CHRU Hôpital d'Enfants</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine PALL-KONDOLFF</last_name>
    </contact>
    <investigator>
      <last_name>Pascal CHASTAGNER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence TARTIER</last_name>
    </contact>
    <contact_backup>
      <last_name>Imène HEZAM</last_name>
    </contact_backup>
    <investigator>
      <last_name>Véronique MINARD-COLIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2011</study_first_submitted>
  <study_first_submitted_qc>May 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2011</study_first_posted>
  <last_update_submitted>July 19, 2017</last_update_submitted>
  <last_update_submitted_qc>July 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhabdomyosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

